Persistent Elevation of Fibrosis Biomarker Cartilage Oligomeric Matrix Protein Following Hepatitis C Virus Eradication

Overview

Journal World J Hepatol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2019 Apr 11

PMID 30967910

Citations 2

Authors

Kristofer Andreasson

Goran Jonsson

Roger Hesselstrand

Hans Norrgren

Affiliations

Soon will be listed here.

Abstract

Serum levels of cartilage oligomeric matrix protein (COMP) has been presented as a biomarker of liver fibrosis in several cross-sectional studies. COMP is also an essential mediator in carcinoma development and has also been associated with hepatocellular carcinoma. We present a prospective analysis of this biomarker in 38 patients with chronic hepatitis C who were subject to eradication therapy with direct acting antivirals. We confirm previous studies associating COMP elevation with liver cirrhosis. We also show how viral levels are correlated with COMP at baseline. In our prospective analysis, we report that successful eradication of hepatitis C results in improvement in liver stiffness and laboratory liver function tests at 1 year follow-up. In contrast, median COMP-levels remain unchanged during the study period. We conclude that the biomarker potential of COMP in the prospective evaluation of liver diseases, remains to be elucidated.

Citing Articles

Duchenne muscular dystrophy trajectory in R-DMDdel52 preclinical rat model identifies COMP as biomarker of fibrosis.

Taglietti V, Kefi K, Bronisz-Budzynska I, Mirciloglu B, Rodrigues M, Cardone N Acta Neuropathol Commun. 2022; 10(1):60.

PMID: 35468843 PMC: 9036715. DOI: 10.1186/s40478-022-01355-2.

Screening and identification of potential biomarkers and therapeutic targets for systemic sclerosis-associated interstitial lung disease.

Huang B, Li J, Zhao J Arch Rheumatol. 2022; 36(4):548-559.

PMID: 35382367 PMC: 8957772. DOI: 10.46497/ArchRheumatol.2021.8625.

References

Crnkic M, Mansson B, Larsson L, Geborek P, Heinegard D, Saxne T . Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther. 2003; 5(4):R181-5. PMC: 165057. DOI: 10.1186/ar760. View

Xiao Y, Kleeff J, Guo J, Gazdhar A, Liao Q, Di Cesare P . Cartilage oligomeric matrix protein expression in hepatocellular carcinoma and the cirrhotic liver. J Gastroenterol Hepatol. 2004; 19(3):296-302. DOI: 10.1111/j.1440-1746.2003.03268.x. View

Li M, Lu S, Liu X, Zhao J, Zhang H, Ling C . [Expression of endoglin in human non-small cell lung cancer and its clinical significance]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013; 29(6):581-4. View

Spitzer M, Wildenhain J, Rappsilber J, Tyers M . BoxPlotR: a web tool for generation of box plots. Nat Methods. 2014; 11(2):121-2. PMC: 3930876. DOI: 10.1038/nmeth.2811. View

Norman G, Gatselis N, Shums Z, Liaskos C, Bogdanos D, Koukoulis G . Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. World J Hepatol. 2015; 7(14):1875-83. PMC: 4506945. DOI: 10.4254/wjh.v7.i14.1875. View

Andreasson K, Hesselstrand R, Saxne T, Holmberg A, Norrgren H, Jonsson G . Cartilage oligomeric matrix protein: a new promising biomarker of liver fibrosis in chronic hepatitis C. Infect Dis (Lond). 2015; 47(12):915-8. DOI: 10.3109/23744235.2015.1075659. View

Miyaki E, Imamura M, Hiraga N, Murakami E, Kawaoka T, Tsuge M . Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatol Res. 2015; 46(8):758-64. DOI: 10.1111/hepr.12621. View

Englund E, Bartoschek M, Reitsma B, Jacobsson L, Escudero-Esparza A, Orimo A . Cartilage oligomeric matrix protein contributes to the development and metastasis of breast cancer. Oncogene. 2016; 35(43):5585-5596. DOI: 10.1038/onc.2016.98. View

Magdaleno F, Arriazu E, Ruiz de Galarreta M, Chen Y, Ge X, Conde de la Rosa L . Cartilage oligomeric matrix protein participates in the pathogenesis of liver fibrosis. J Hepatol. 2016; 65(5):963-971. PMC: 5831373. DOI: 10.1016/j.jhep.2016.06.003. View

10.

Zachou K, Gabeta S, Shums Z, Gatselis N, Koukoulis G, Norman G . COMP serum levels: A new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis. Eur J Intern Med. 2017; 38:83-88. DOI: 10.1016/j.ejim.2017.01.007. View

11.

Huang R, Xia J, Yan X, Liu Y, Wu C . Serum cartilage oligomeric matrix protein levels as a novel non-invasive biomarker for liver fibrosis in patients with chronic viral hepatitis? It is too early. Eur J Intern Med. 2017; 42:e24. DOI: 10.1016/j.ejim.2017.04.009. View

12.

Andreasson K, Waldenstrom J, Westin J, Norrgren H, Jonsson G, Nystrom K . Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection. J Hepatol. 2017; 67(3):649-651. DOI: 10.1016/j.jhep.2017.03.043. View

13.

Vermehren J, Park J, Jacobson I, Zeuzem S . Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol. 2018; 69(5):1178-1187. DOI: 10.1016/j.jhep.2018.07.002. View